Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.